ÖNERİLEN KAYNAKLAR:

1. Abdulnour-Nakhoul S, Bor S, Imeryuz N, Orlando RC Mechanisms of basolateral Na+ transport in rabbit esophageal epithelial cells. Am J Physiol 1999 Feb;276(2 Pt 1):G507-17
2. Achem SR, Robinson M. A prokinetic approach to treatment of gastroesophageal reflux disease. Dig Dis 1998 Jan-Feb;16(1):38-46
3. Beckloff GL, Chapman JH, Shiverdecker P. Objective evaluation of an antacid with unusual properties. J Clin Pharmacol. 1972: 12; 11.
4. Behar J, Sheahan DG, Biancani P, Spiro HM, Storer EH. Medical and surgical management of reflux esophagitis: a 38-month report on a prospective clinical trial. N Engl J Med. 1975: 293; 263,
5. Bor S, Ersin S, Tuncer K, Günşar F, Yararbaş Ö, Çavuşoğlu H. Reflü cerrahisinde preoperatif ayrıntılı değerlendirmenin önemi. XVII. Ulusal Gastroenteroloji Kongresi. 2000. Antalya.
6. Bor S, Caymaz-Bor C, Tobey NA, Abdulnour-Nakhoul S, Marten E, Orlando RC. The effect of ethanol on the structure and function of rabbit esophageal epithelium. Am J Physiol. 1998; 274 (Gastrointest and Liver Physiol 37): G819-G826.
7. Bor S, Caymaz-Bor C, Tobey NA, Abdulnour-Nakhoul S, Orlando RC. Esophageal exposure to ethanol increases the risk of acid damage in rabbit esophagus. Dig Dis Sci. 1999; 44 (2); 290-300.
8. Bor S, Vardar R, Günşar F, Alkanat M, Alev M, Akarca US, Afşar İ, Tunçyürek M. Gastrik kardiada intestinal metaplazi sıklığı. XVI. Ulusal Gastroenteroloji Kongresi. Kasım 1999. Kemer Antalya.
9. Bor S, Yıldız C, Günşar F, Kaya S, Çavuşoğlu H. Gastroözofageal reflü sendromunda omeprazol ve lansoprazolun gastrik ve özofageal asidi inhibe edici etkilerinin karşılaştırılması. XVI. Ulusal Gastroenteroloji Kongresi. Kasım 1999. Kemer Antalya.
10. Bor S. Gastroözofageal reflü sendromu etyopatogenezinde özofagus epitel direncinin önemi. Güncel Gastroenteroloji. 1997; 1/2: 171-183.
11. Bor, S Mandiracioglu A, Kitapcioglu G, Caymaz-Bor C, Zeytinoglu H, Gilbert RJ. Gastroesophageal reflux disease in an urban population in Turkey.: a developing nation with high H. Pylori prevalence. Gastroenterology, April 2001 suppl.
12. Bradley LA , Richter JE, Pulliam TJ, Haile JM, Scarinci IC, et al. The relationship between stress and symptoms of gastroesophageal reflux: the influence of psychological factors. Am J Gastroenterol. 1993; 88: 11.
13. C. Yıldız, S.Bor. Barrett Özofagusu. Güncel Gastroenteroloji. 2000;
14. Caestecker JS. Diet and reflux. Motility, 1991: 15; 4-5.
15. Castell DO Castell DO, Richter JE, Robinson M, Sontag SJ, Haber MM. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol. 1996: 91; 1749.
16. Castell DO, Dalton CB, Becker D, Sinclair J, Castell JA. Alginic acid decreases postprandial upright gastroesophageal reflux. Comparison with equal strenght antacid. Dig Dis Sci. 1992: 37; 589.
17. Castell DO. Future medical therapy of reflux esophagitis. J Clin Gastroenterol. 1986; 8 (suppl 1): 81.
18. Castell DO. The Esophagus. Little Brown & Comp. 1999.
19. Castell DO. The lower esophageal sphincter: phsysiologic and clinical aspects. Ann Intern Med. 1975: 83; 390.
20. Clark CS, Kraus BB, Sinclair J, Castell DO. Gastroesophageal reflux induced by exercise in healthy volunteers. JAMA 1989 Jun 23-30; 261(24): 3599-601
21. Cohen S. Pathogenesis of coffee-induced gastrointestinal symptoms. N Engl J Med. 1980; 303:122.
22. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries T/J Double-blind comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther. 1999: 13; 49-57.
23. DeVault KR. Current management of gastroesophagal reflux disease. The Gastroenterologist, 1996: 4; 24-32.
24. Domestic International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol 1999; 34: suppl 231.
25. Fraser-Moodie CA, Norton B, Gornall C, Magnago S, Weale AR, Holmes GK Weight loss has an independent beneficial effect on symptoms of gastro-oesophageal reflux in patients who are overweight. Scand J Gastroenterol 1999 34(4):337-40.
26. Gallup Survey. Heartburn across America. Princeton, NJ: Gallup Organization,1998 Mar 24 (Erişilemiyor. Bu yayın hakkında bilgi için yazıya bakınız)
27. Glise H, Hallerback B, Johansson B. Quality of life assessments in the evaluation of gastroesophageal reflux and peptic ulcer disease before, during and after treatment. Scand J Gastroenterol Suppl 1995;208:133-5
28. Günşar F, Bor S. Kardiyak Kökenli Olmayan Göğüs Ağrılarına Yaklaşım. Güncel Gastroenteroloji. 1999; 3/2: 148-157,
29. Halloway RH, Dent J. Medical treatment of gastroesophageal reflux disease-beyond the proton pomp inhibitors. Dig Dis. 2000: 18; 7-13.
30. Hamilton JW, Boisen RJ, Yamamoto DT, Wagner JL, Reichelderfer M. Sleeping on a wedge diminishes exposure of the esophagus to refluxed acid. Dig Dis Sci. 1988; 33: 518-522.
31. Hatlebakk JG, Katz PO, Sykehus H. The medically refractory patient: when proton pump inhibitors fail. AGA Postgraduate Course Syllabus. 1999. 21-25.
32. Heller SR, Fellows IW, Ogilvie AL, Atkinson M. Non-steroidal anti-inflammatory drugs and benign esophageal stricture. Br Med J. 1982: 285; 167-168.
33. Higgs RH, Smyth RD, Castell DO. Gastric alkalinization: Effect on loweresophageal sphincter pressure and serum gastrin. N Engl J Med. 1974: 291; 486-490.
34. Johnson LF, DeMeester TR. Twenty-four hour pH monitoring of the distal esophagus. Am J Gastroenterol. 1974; 62: 325.
35. Kahrilas PJ, Gupta RR. Mechanisms of acid reflux assiciated with cigarette smoking. Gut, 1990; 31: 4-10.
36. Katz LC, Just R, Castell DO. Body position affects recumbent postprandial reflux. J Clin Gastroenterol. 1994; 18 (4): 280.
37. Klinkenberg-Knoll EC, Nelis F, Dent J, Snel P, Mitchell B et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa. Gastroenterology, 2000; 118: 661-669.
38. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HPM et al. Atrophic gastritis and Helicobacter pylori infection in patients with refluz esophagitis treated with omeprazole or fundoplicaton. New Engl J Med. 1996; 334: 1018-1022.
39. Lagergren J, Bergstrom R, Nyren O No relation between body mass and gastro-oesophageal reflux symptoms in a Swedish population based study. Gut 2000 Jul;47(1):26-9
40. Lew EA, Barbuti RC, Kovacs TOG et al. An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810). Aliment Pharmacol Ther 1998; 12: 667-72.
41. Lieberman DA. Medical therapy for chronic reflux esophagitis: long-term follow-up. Arch Int Med. 1987: 147; 1717.
42. Locke GR 3d, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112(5):1448-56
43. Locke GR 3d. The epidemiology of functional gastrointestinal disorders in North America. Gastroenterol Clin North Am 1996;25(1):1-19
44. Long JD, Marten E, Tobey NA, Orlando RC. Luminal hypertonicity and the susceptibility of rabbit esophagus to acid injury. Dis Esophagus 1998; 11(2): 94-100.
45. Mandel KG, Daggy BP, Brodie DA, Jacoby HI. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment PharmacolTher. 2000: 14; 669-690.
46. Martinek J, Blum Al, Stolte M, Hartmann M, Verdu EF, Luhmann R. Effects of pumaprazole (BY-841), a novel reversible proton pomp antagomist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection. Aliment Pharmacol Ther. 1999: 13; 27-34.
47. Moss HA et al. Anti-reflux agents:stratification or flotation? Eur J Gastroenterol Hepatol. 1990: 2; 45.
48. Mossner J, Holscher AH, Herz R, Schneider A. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment Pharmacol Ther. 1995: 9; 321.
49. Mungan Z, Demir K, Onuk MD, Göral V, Boztaş G, Beşışık F, Yıldırım B, Yeğinsu O. Gastroözofageal reflü hastalığının ülkemizdeki özellikleri. Turkish Journal of Gastroenterology, 1999;10(2):101-108
50. Nebel O, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Dig. Dis. 1976. 21 (11); 953-6.
51. Nebel OT, Castell DO. Lower esophageal sphincter pressure changes after food ingestion. Gastroenterology, 1972: 63; 778-783.
52. Orlando RC. Reflux Esophagitis. In: Yamada T, ed. Textbook of Gastroenterology. Second Edition. JB Lippincott Company, Philadelphia, 1995: 1214-1242.
53. Piquette RK. Torsade de pointes induced by cisapride/clarithromycin interaction. Ann Pharmacother 1999 Jan;33(1):22-6
54. Price SF, Smithson KW, Castell DO. Food sensitivity in reflux esophagitis. Gastroenterology, 1978: 75; 240-43.
55. Ramirez B, Richter JE, Review article: promotility drugs in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1993: 7; 5-20.
56. Revicki DA, Wood M, Maton PN, et al. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998;104(3):252-8
57. Robinson M, Thjodleifsson B, Dekkers C et al. Normalising pathological oesophageal acid exposure correctly predicts response in a phase III GORD trial. Digestion 1998; 59 (Suppl 3): 582.
58. Salmon PR et al. Effect of coffee on human lower esophageal function. Digestion, 1981; 21: 69.
59. Schofield PM, Whorwell PJ, Brooks NH, Bennett DH, Jones PE Oesophageal function in patients with angina pectoris: a comparison of patients with normal coronary angiograms and patients with coronary artery disease. Digestion 1989;42(2):70-8
60. Sivri B. Gastroözofageal reflü hastalığı. Gastroenteroloji. Ed: H Telatar, H. Şimşek. Hekimler Yayın Birliği, Ankara. 1993. 171-183.
61. Sontag SJ. The medical management of reflux esophagitis. Role of antacids and acid inhibition. Gastroenterol Clin North Am. 1990: 19; 683-712.
62. Thomas FB et al. Inhibitory effect of coffee on lower esophageal sphincter pressure. Gastroenterology, 1980; 79:1262.
63. Tobey NA, Sikka D, Marten E, Caymaz-Bor C, Hosseini SS, Orlando RC. Effect of heat stress on rabbit esophageal epithelium.Am J Physiol 1999 Jun; 276 (6 Pt 1): G1322-30
64. Vardar R, Bor S, Günşar F, Alkanat MB, Özütemiz Ö, Aydın A, Tunçyürek M, Musoğlu A, İlter T, Çavuşoğlu H. Mide tümörü lokalizasyonlarında değişmeler. XVI. Ulusal Gastroenteroloji Kongresi. Kasım 1999. Kemer Antalya.
65. Verlinden M. Review article: a role for gastrointestinal prokinetic agents in the treatment of reflux oesophagitis? Aliment Pharmacol Ther 1989 Apr;3(2):113-31
66. Voskuil JH, Cramer MJ, Breumelhof R, Timmer R, Smout AJ Prevalence of esophageal disorders in patients with chest pain newly referred to the cardiologist. Chest 1996 May;109(5):1210-4
67. Walker AM, Szneke P, Weatherby LB, Dicker LW, Lanza LL, Loughlin JE, Yee CL, Dreyer NA. Am J Med 1999 Oct;107(4):356-62 The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada.
68. Walsh JH, Pounder R, Dammann HG, Humphries TJ. Rabeprazole 20 mg is optimal therapy for acute acid related diseases: pharmacodynamic perspective. Digestion 1998; 59 (Suppl 3): 234.
69. Wilson LJ, Ma W, Hirschowitz BI. Association of obesity with hiatal hernia and esophagitis. Am J Gastroenterol 1999 Oct;94(10):2840-4.
70. Wurst W, Hartmann M. Current status of acidd pump antagonists (reversible PPI's). Yale J Biol Med. 1996: 36; 233-243.
71. Yazaki E, Shawdon A, Beasley I, Evans DF. The effect of different types of exercise on gastro-oesophageal reflux.Aust J Sci Med Sport.1996 28(4):93-6

1 1 1 1 1 1 1 1 1 1 Beğeni 0.00 (0 Oy)